Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

Stopped FDA and Ipsen alignelment: Due to unfeasibility and the resulting inability to meet the required enrolment targets. No safety concerns

Conditions

• Advanced Soft-tissue Sarcoma
• Advanced Epithelioid Sarcoma

Interventions

• DRUG: Tazemetostat
• DRUG: Doxorubicin HCl

Sponsor

Epizyme, Inc.